Kezar Life Sciences Inc KZR

Healthcare Biotechnology

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company’s lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. It is also developing KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

NDAQ:KZR - Post by User

Kezar Life Sciences Inc

<< Previous

Bullboard Posts

Next >>

(4)
•••

Post by AviseAnalyticson Jun 30, 2022 7:33am

139 Views

Post# 34793027

KEZAR MAKES A SOLID COMEBACK!

$KZR

Kezar Life Sciences, Inc. (NASDAQ: KZR), a clinical-stage biotechnology company, reported positive top-line results from the Phase 2 clinical trial named MISSION, evaluating zetomipzomib, a novel, first-in-class selective immunoproteasome inhibitor, in patients with active lupus nephritis (LN).

The Company made a solid comeback after a setback in May 2022, when top-line results from a Phase 2 study showed that the candidate failed to beat a placebo in a trial evaluating zetomipzomib as a treatment for dermatomyositis or polymyositis.

Read on to find out more!

https://www.aviseanalytics.com/kezar-makes-a-solid-comeback/

<< Previous

Bullboard Posts

Next >>

Aggressive drilling plans target gold and silver hotspots in Nevada